Las Vegas, USAPolymyositis Pipeline to Progress with New and Emerging Drugs for Treatment, Analyzes , Dec. 08, 2021 (GLOBE NEWSWIRE) -- DelveInsight’s ‘Polymyositis Pipeline Insight 2021’ report ...

Please provide your email address to receive an email when new articles are posted on . Among systemic rheumatic diseases, the risk for opportunistic infection is highest among patients with ...

Q: Which doctor should I consult for polymyositis? A: A neurologist or rheumatologist must be consulted first and additional expertise may be required from a pulmonologist, physiotherapist and speech ...

CORONA, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Many patients who might have previously been diagnosed with polymyositis are now being treated for ...

PF1801 is a novel long-acting glucagon-like peptide-1 receptor agonist. The Food and Drug Administration (FDA) has granted Orphan Drug designation to PF1801 for the treatment of polymyositis.

LONDON--(BUSINESS WIRE)--Technavio has announced their latest pipeline analysis report on the polymyositis market. The report includes a detailed analysis of the pipeline molecules under investigation ...

Systemic Lupus Erythematosus (SLE): SLE is an autoimmune disorder in which the immune system of the body attacks its own cells instead for fighting against foreign bacteria and other harmful ...

The alternative text for this image may have been generated using AI. New research from Tokyo, Japan could help clarify the role of proinflammatory mediators in the pathogenesis of chronic ...

Nearly one-third of PM/DM patients are readmitted within 180 days. Common causes of readmission include PM exacerbations and sepsis. Female patients, obese patients, patients with comorbid conditions, ...

We report two cases of chronic GVHD presenting with polymyositis manifestations 13 and 19 months after allogeneic hematopoietic stem cell transplant, successfully treated with corticosteroids and ...